Posts by Jessica J. Lin, MD
-
ASCO 2024 Meeting Highlights
Priscilla Brastianos, MD, Lecia Sequist, MD, MPH, and Jessica Lin, MD, share highlights from the ASCO 2024 conference, including encouraging results from a clinical trial for patients with high grade meningiomas, a new treatment for stage III unresectable EGFR lung cancer, and a palliative care trial.
-
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
Researchers at the Massachusetts General Hospital Cancer Center and colleagues have identified mutations that make lung cancer resistant to adagrasib and other KRAS-G12C inhibitors. Their findings provide clues to designing next-generation inhibitors and combination regimens.
Biography
Jessica J. Lin, MD, is an attending physician in the Center for Thoracic Cancers and Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital. She is an Assistant Professor of Medicine at Harvard Medical School.
Dr. Lin earned her bachelor’s degree in Biochemistry at Harvard College and medical degree from Harvard Medical School. She completed her internship and residency in internal medicine at Brigham and Women’s Hospital, serving as Chief Medical Resident at Brigham and Women’s Faulkner Hospital. She subsequently trained in the Dana-Farber/Mass General joint hematology/oncology fellowship program.
Dr. Lin cares for patients with lung cancer and other thoracic malignancies, and additionally performs clinical and translational research. Dr. Lin’s major research interests include studying driver oncogene alterations in non-small cell lung cancer and development of resistance to targeted therapies. She leads clinical trials of novel targeted therapy and immunotherapy agents in lung cancer. Her work has been recognized by awards and grants from organizations such as the Conquer Cancer Foundation/American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and prIME Oncology.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
